Table 5

Subgroup analysis by hormone receptor status of the benefit from taxane-containing adjuvant chemotherapy regimens

HR (95% CI) for DFS


Study

Design

Number of patients

Stratification by hormone receptor status

Hormone receptor positive

Hormone receptor negative


CALGB 9344 [14,65]

AC × 4 versus AC × 4 → P × 4

3,121

No

0.88 (0.75–1.03)a

0.77 (0.64–0.88)

NSABP B-28 [15]

AC × 4 versus AC × 4 → P × 4

3,060

Nob

0.77 (0.65–0.92), P = 0.004

0.90 (0.72–1.12), P = 0.33

GEICAM 9906 [16]

FEC × 6 versus FEC × 4 → wP × 8

1,248

No

0.79 (0.54–1.15), P = 0.216

0.76 (0.51–1.12), P = 0.163

HE 10/97 [17,42]

E × 4 → CMF × 4 versus E × 3 → P × 3 → CMF × 3 (q2w)

604

Yes

0.90 (0.63–1.29)

0.69 (0.37–1.30)

E 2197 [38]

AC × 4 versus AT × 4

2,952

Yes

0.99 (0.75–1.30), P = 0.96c

1.21 (0.92–1.59), P = 0.17c

USO 9735 [72]

AC × 4 versus TC × 4

1,016

No

0.71 (0.47–1.08)

0.64 (0.38–1.04)

BIG 02-98 [25]

A × 4 → CMF × 3 versus AC × 4 → CMF × 3 versus A × 3 → T × 3 → CMF × 3 versus AT × 4 → CMF × 3

2,887

No

D versus control: 0.86 (0.71–1.03) Sequential D versus sequential control: 0.79 (0.61–1.05)

D versus control: 0.89 (0.69–1.15) Sequential D versus sequential control: 0.80 (0.55–1.15)d

BCIRG 001 [20]

FAC × 6 versus TAC × 6

1,491

No

0.72 (0.56–0.92)

0.69 (0.49–0.97)

PACS 01 [21]

FEC × 6 versus FEC × 3 → T × 3

1,999

No

0.82 (0.63–1.07)

0.79 (0.57–1.11)

E 1199 [32]

AC × 4 → P × 4 all q3w versus AC × 4 → P × 12w versus AC × 4 → D × 4 all q3w versus AC × 4 → D × 12w

4,950

Yes

1.31 (1.00–1.72), P = 0.05e

1.37 (0.98–1.93), P = 0.07e


Subgroup analysis by hormone receptor status of the benefit from taxane-containing adjuvant chemotherapy regimens in different reported clinical trials (Modified from Martin and coworkers [67]). aDifferences in DFS were no longer significant after adjusting for multiple comparisons. bPatients aged 45 years with hormone receptor positive tumors and all patients who were 50 years or older regardless of hormone receptor status were given tamoxifen concomitantly with chemotherapy; tamoxifen use was a stratification factor. cHR of AT versus AC and HR>1 favors the taxane arm. dPatients with hormone receptor-negative disease exhibited the largest absolute improvement in 5-year DFS when the sequential docetaxel arm (A → D → CMF) was compared with the control arms; these group had a 7% or more absolute increase in 5-year DFS compared with either control arm or the concurrent docetaxel arm. eHR>1 favors the weekly paclitaxel arm. A, doxorubicin; C, cyclophosphamide; DFS, disease-free survival; E, epirubicin; F, 5-fluorouracil; T, docetaxel; w, week.

López-Tarruella and Martín Breast Cancer Research 2009 11:204   doi:10.1186/bcr2226